INS and type 1 diabetes mellitus: In the EASE trials (368, 369), administration of empagliflozin (2.5, 10, or 25 mg) along with insulin to overweight people with T1D for 26 to 52 weeks, induced a progressive reduction in HbA1c from 0.28 to 6.4%, body weight from 0.54 to 13.3%, and insulin dose per day from 0.53 to 12.7%.